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The interest in studying neuroimmune interactions is increasing in the scientific community, and for many researchers, immunity
is becoming a crucial factor in the understanding of the physiology of the normal brain as well as the biology underlying
neurodegenerative diseases. Mounting data over the last two decades point toward immune and inflammatory alterations as
important mediators of the progressive dopaminergic degeneration in Parkinson’s disease.The purpose of this review is to address,
under a historical perspective, as well as in the light of recent reports, the glial-mediated inflammatory and immune responses that
occur in Parkinsonism. In line with this, this review also evaluates and highlights available anti-inflammatory drugs and putative
targets for Parkinson’s disease therapy for the near future.
1. Introduction
After many decades of research, the cause of idiopathic
Parkinson’s disease (PD) remains unknown. A number of
hypotheses have been put forward to explain the origin of
the disease. However, the understanding of the mechanisms
underlying PD remains inconclusive.The trigger of dopamin-
ergic degeneration seems to be multifactorial and, therefore,
affected by both endogenous and environmental elements. In
the light of recent epidemiological, genetic, and experimental
studies, inflammation and immune responses are considered
as important mediators of dopaminergic degeneration. Large
population studies have come to conclude that individuals
taking nonsteroidal anti-inflammatory drugs (NSAIDs) have
less risk of suffering idiopathic PD, which suggest that anti-
inflammatory drugs may be a promising disease-modifying
treatment for Parkinsonian patients [1–4]. Important genetic
studies have shown an increase of polymorphisms of the
human leukocyte antigen (HLA)-DR type gene in sporadic
PD, indicating an immune/inflammatory-related component
of the disease [5, 6]. Despite the extended basic research
performed in experimental models of PD and the positive
outcome of a wide range of tested anti- inflammatory drugs,
the translational aspect toward a neuroimmune-modifying
therapy in PD has been rather slow. In recent years, some
pharmacological companies have taken steps towards the
development of therapeutic programs. New trial phases
have recently been started to implement anti-inflammatory
treatments for the near future. There are a number of clinical
trials, essentially focused on monitoring the evolution of
the inflammatory response in the brain of PD patients in
vivo, using potential imaging biomarkers in the course of
dopaminergic degeneration. [123-I] CLINDE, [18F] FEPPA,
and [(11)C] PBR28 are some of the compounds that are being
evaluated in Europe and North America for their capacity to
detect neuroinflammation in Parkinsonian patients by single-
photon emission computed tomography (SPECT) (source:
NIH website, http://www.clinicaltrials.gov/). The outcome of
these trials will provide crucial data to test and monitor
the progression of anti-inflammatory treatments for PD in
the future and will help to define the timely therapeu-
tic window to avert, or at least decelerate, inflammatory-
mediated dopaminergic degeneration. In the following sec-
tions of this review, the inflammatory and immune responses,
previously described in Parkinsonism, are evaluated in a
historical perspective. Then, considering the recent advances
achieved in PD patients and animal models of PD, the main
aspects and mechanisms of glial-mediated inflammation
during dopaminergic degeneration are reassessed, suggesting
putative and inflammatory drugs for therapeutic purposes.
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2. Historical Perspectives on Inflammatory
Response in Parkinsonism
2.1. Postencephalitic Parkinsonism: An Immune-Mediated Par-
kinsonian Syndrome. Since the description of the encephali-
tis lethargica by von Economo in 1917, the idea that inflamma-
tory responses or immune-mediated events might contribute
to the degeneration of dopaminergic neurons had been sug-
gested [7].The patients affected by von Economo’s encephali-
tis displayed clinical Parkinsonian signs that overlapped with
the idiopathic PD syndrome and showed degeneration in
basal ganglia areas and midbrain neurons of the substantia
nigra (SN) [8]. The necrosis of the SN could be either
unilateral or bilateral and showed a widespread gliosis [9]
with prominent glial scars in the SN [10]. In the late 60s and
early 70s, new isolated cases of encephalitis with Parkinso-
nian symptoms also confirmed the inflammatory necrosis
of the SN [8, 11], suggesting that specific inflammatory
responses might have neurological effects with Parkinsonian
appearance.
The cause of postencephalitic Parkinsonism remains
uncertain. It is thought that a viral infection could be the
trigger of the disease. Interestingly, in the study of recent
cases, the fact that specific variants of influenza virus, like
H5N1, may cause encephalitis, together with the experimen-
tal verification that it can be transferred from birds to mam-
mals, supports the hypothesis that H5N1 epidemic infections
may have Parkinson-like neurological consequences [12]. In
line with this, a recent review highlights that among all the
influenza epidemics that occurred in the 20th century, only
von Economo’s encephalitis had a well-described Parkinson-
like syndrome [13]. Furthermore,H5N1 influenza virus is able
to enter the brain and induce Parkinsonism in mammals,
which makes this type of virus the most plausible cause for
the 1917 pandemic [14].
These facts and historical evidence suggest a clear paral-
lelismbetween postencephalitic Parkinsonism and idiopathic
PD and sustain the hypothesis of a possible common factor
for both Parkinsonian syndromes. Postencephalitic Parkin-
sonism was initially treated with anti-inflammatory drugs,
usually corticoids, because an infectious origin was assumed.
However, the clinical and histological coincidences with PD
suggested the use of L-DOPA as a treatment for Parkin-
sonian encephalitis. Initially, patients had an encouraging
and surprising positive response to L-DOPA treatment, but
unfortunately the response was reversible not durable and
induced severe side effects [15].
After von Economo’s epidemic, the link between Parkin-
sonism and immunity has been further analyzed, and has
led to hypothesize that infectious or immune-related factors
may critically affect PD [7, 16]. Since the origin of PD
is unknown, the comparison between both syndromes is
still intriguing. The fact that a well-known inflammatory
or immune response is able to induce a particular Parkin-
sonism in encephalitis lethargica suggests that idiopathic
PD could as well be caused, or at least aided, by an
underlying, yet poorly understood, immune or inflammatory
response.
2.2. First Descriptions of Glial-Mediated Inflammatory Re-
sponses in PD and MPTP-Induced Parkinsonism. In 1988,
McGeer and coworkers described for the first time that the
areas of dopaminergic degeneration of brains from patients
who died with PD showed clear signs of neuroinflamma-
tion, characterized by the activation of microglial cells [17].
Importantly, the activation ofmicroglia was detected through
the increase of the HLA-DR expression, suggesting active
nerve degeneration. The impact of this publication at that
time was discrete, since it seemed obvious that local neuro-
inflammation in the neighboring glia was a causative effect
of the neuronal degeneration.However,McGeer’s publication
became years later one of the most prominent breakthroughs
for the understanding of the inflammatory responses in PD.
In 1999, the publication of the he first postmortem analysis
performed in three cases of the so-called Frozen Addicts,
described by Dr. Langston, transformed the scenery of this
field of research [18]. In 1982, in Santa Clara, California,
a group of young people was diagnosed with a severe
Parkinsonian syndrome, showing almost identical clinical
signs to idiopathic PD. All of them were drug addicts who
received heroin from a commonprovider.Then,Dr. Langston
and his team, in collaboration with the National Institute of
Health, determined that the heroin that they consumed was
contaminated with a neurotoxin called 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) that injected intravenous
in primates causing a permanent Parkinsonian syndrome
[19, 20]. Three of these patients died at the end of the 90s,
and the first postmortem studies revealed that the SN cells
were depleted, as what occurred in PD patients [18]. The
areas of dopaminergic degeneration showed activemicroglia,
expressing high levels of HLA-DR, identical to McGeer’s
observations described years before in PD brains [18]. This
data demonstrated that a still active nerve degeneration was
ongoing many years after the neurotoxic insult, suggesting
that microglial cells may initiate a neuroinflammatory cycle
in the areas of degeneration that contribute to the neuronal
death. Importantly, in these particular cases, a single set
of injections of MPTP, taking place almost 15 years before,
were able to initiate a persistent inflammatory response
affecting the conditions of remnant dopaminergic neurons
for decades. This phenomenon was mimicked in monkeys,
and microglial activation could be observed in the SN
years after the neurotoxin insult [21] even without L-DOPA
treatment [22], which supported even more strongly that
solely the initialMPTP insult was able to originate a persistent
neuroinflammation in dopaminergic areas. Therefore, the
question that had to be answered, and still has, is whether
this glial-mediated inflammatory response is able to induce
or influence neuronal degeneration.
3. Glial-Mediated Inflammation
in Parkinsonism
3.1. Role of Microglial Cells in the Proinflammatory Envi-
ronment in Parkinsonism. The study of the inflammatory
response in PD has been essentially focused on the study of
microglia in the neurodegenerative process [23–25]. Despite
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the increasing data and publications over the last two decades,
microglia’s role in PD is still unclear and not fully understood.
The reason why microglial cells remain activated during
years in Parkinsonian individuals, such in PD- and MPTP-
intoxicated patients [17, 18], is still a difficult fact to evaluate
and understand. The expression of HLA-DR in humans is
usually associated with active neuronal degeneration, but
there are reasonable doubts on whether microglial activation
is a cause or a mere consequence of the neuronal death.
In humans and nonhuman primates, the exploration of
microglial activation at different time points entails serious
technical limitations. It becomes really challenging to assess
which phenomenon occurs first and whether long-term
neuro-inflammation is able to induce new dopaminergic
degeneration in vivo or not [21, 22]. In patients with PD,
studies performed with position emission tomography with
a radiotracer for activated microglia [(11)C](R)-PK11195 and
a dopamine transporter marker [(11)C]CFC show inter-
esting and clarifying results. Microglial activation can be
detected in patients in the nigrostriatal pathway in vivo
through the radiotracer [(11)C](R)-PK11195, which appears
increased in PD comparedwith healthy subjects. Importantly,
patients with early PD show a significant correlation between
microglial activation [(11)C](R)-PK11195 and dopaminergic
terminal loss [(11)C]CFC, which indicates a direct effect of
inflammation on neuronal degeneration [26]. However, in
long-term Parkinsonian patients, microglial activation mea-
sured by [(11)C](R)-PK11195 remains persistently increased
in stable levels during years even when the dopaminergic
loss progresses over time [27]. Coherently with these results,
postmortem studies in monkeys show that either acute or
chronic protocols of MPTP administration are able to induce
similar levels ofmicroglial-mediated inflammatory responses
[28].
This evidence indicates that in humans and non-humans
primates, microglial activation gets rapidly activated in the
first stages of dopaminergic degeneration and then main-
tained active during years once a particular threshold of
activation is reached.Therefore, glial-mediated inflammation
in Parkinsonism in primates seems to be critical in the early
phases of dopaminergic degeneration and indicates that this
period may be relevant as a timely therapeutic window.
By contrast, in Parkinsonian mice, microglial activation is
transient and goes back to basal levelswhen the dopaminergic
degenerative process is resolved (Figure 1) [29, 30]. Very
little is known about why glial cells perform differently
between species but it is clear that rodents and primates
have a different regulatorymechanism driving glial responses
after dopaminergic insult. The investigation of these species-
dependent differences may represent one of the key pieces
to understand the neuropathological puzzle that links glial-
mediated inflammation with neuronal degeneration.
The triggering of microglial activation is mediated by
several factors. In basal conditions, microglial cells are
in constant surveillance in the brain parenchyma and are
susceptible to undergo important morphological arrange-
ments according to the changes of the microenvironment
[31, 32]. The initial steps of the neuronal degeneration are
associated with the release of a number of signals that
induce the microglial activation and polarization toward
the damaged neurons. It is known that P2Y receptors are
very important players in the motility and polarization of
microglial cells [33, 34]. Degenerating neurons release or
leak ATP, which activates microglial P2Y receptors, attract-
ing microglia toward the ATP gradient [33–35]. A recent
report also demonstrates that degenerating neurons signal
particular calcium waves, attracting neighboring microglial
cells into the area of local damage [36]. These signals recruit
microglial cells, which are able to move their branches and
their cell bodies toward the area of degeneration [33]. The
final purpose of this motility is to restore the tissue and
remove debris from the areas of degeneration (Figure 2),
but the details of how this process takes place in adult
mammals in the neurodegenerative process are not fully
understood. It is thought that microglial cells move to engulf
particles as a key function of the immune response in the
brain. Previous reports have shown that microglial cells
are able to phagocyte fluorescent microspheres, opsonized
beads, or fluorescently labeled 𝛽-amyloid, which addresses
the phagocytic properties of microglia [37–39]. Experiments
performed in zebrafish embryo have demonstrated that
microglia phagocytose neurons in brain development [40].
On the other hand, in adults, apoptotic newborn cells are
phagocytosed bymicroglial branches forming ball-and-chain
structures, a crucial phenomenon for the homeostasis of the
brain parenchyma [41]. Although it is assumed that microglia
may phagocyte neurons in CNS diseases, how the engulf-
ing process takes place in neurodegeneration is still under
investigation. Recently, we have reported that microglial cells
phagocytose entire dopaminergic neurons in a one-to-one
ratio in a mouse model of PD. This process involves a
complex machinery where microglia arrange their F-actin
cytoskeleton forming a structure, named gliapse, inwhich the
entire microglial cell body is closely apposed to the damaged
neuron, polarizing its filopodia toward the neuronal cell body
and placing the organelles toward the cell-to-cell interface
(Figure 2) [42]. Microglial cells, following “find-me” and
“eat-me” signals released from degenerating neurons, acti-
vate Rho-kinase- (ROCK-) and Cdc42-dependent motility
cascades, which are crucial in the cytoskeletal rearrangement
(Figure 3). Microglial motility and polarization end up in the
intimate apposition to the degenerating neuron, engulfing
and digesting the dying neuronal body [42]. These lines of
evidence give new details and insights of how microglial
cells contribute to the dopaminergic degeneration. Further
studies in experimental models of PD and the comparison
with the human disease will be critical to better understand
the particular role of microglia in this pathological scenario
and find new therapeutic approaches to arrest microglial cells
and to avert proinflammatory environment of PD.
3.2. Role of Astrocytes in the Proinflammatory Environment
in Parkinsonism. Besides the prominent functions played by
microglial cells, astrocytes also participate actively in the
neuroinflammatory response [43]. Astrocytic reaction has
generally been considered as an essential event in forming
the so-called glial scar [44, 45], however, in the light of
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Figure 1: Timing of cytokine release, glial activation, and T-cell infiltration in the inflammatory response in Parkinsonism. Within 24 h,
cytokine release and microglial activation can be clearly observed. According to the protocol of dopaminergic cell death induction, cytokine
release andmicroglial activation can be resolved around 72 h. Maximum peak of T-cell infiltration can be achieved at 48 h after dopaminergic
insult. Astroglial activation can be seen at 24 h but reaches the maximum peak at 72 h. Depending on the protocol of dopaminergic cell death
induction used, the inflammatory response may be resolved within 72 h.
more recent data, it is well known that astrocytes play a
more complex role in the neurodegenerative and restorative
process [44, 46–48]. Astroglial cells become reactive in many
neurodegenerative alterations such as PD [49]. The areas
of neurodegeneration of PD patients show high expression
of glial fibrillary acidic protein (GFAP) [17, 50, 51], which
is a compound of the astrocytic cytoskeleton that indicates
reactivity of astrocytes. Astrogliosis is seen in other forms
of Parkinsonism, such as postencephalitic Parkinsonism [52]
andMPTP-induced Parkinsonism in intoxicated humans [18]
or non-human primates [22]. As microglial cells, astrocytes
become reactive after the dopaminergic insult. In mice, the
astrogliosis is transient, while in primates it persists during
months or years (Figure 1). The presence of astroglial cells
with reactive phenotype, such as the increase of GFAP, is
considered part of a neuroprotective process [46, 53]. In
the case of the dopaminergic pathway in Parkinsonism, the
most vulnerable regions of the mesencephalon, specifically
the subregions of the SNpc, showvery lowdensity of astroglial
cells compared with less vulnerable dopaminergic areas of
the mesencephalon, which suggests that the endogenous
presence of astroglia represents a factor for neuroprotection
[54]. However, the mechanisms driving this protective role
in Parkinsonian degeneration are still unclear. Astrocytes
are able to release many factors that may contribute to the
restoration of the degenerated tissue [55]. Glial-derived neu-
rotrophic factor (GDNF), among others, is a good example.
GDNF is produced and released by astrocytes [56] and it has
a beneficial effect in experimental models of Parkinsonism
[57–59]. Unfortunately, GDNF therapeutic benefit for PD
patients has been controversial and not conclusive [58, 60].
Other factors, such as astrocytic brain-derived neurotrophic
factor (BDNF) [61, 62], neurotrophin-3 (NT-3) [62], or mes-
encephalic astrocyte-derived neurotrophic factor (MANF)
[63] are also involved in the neuroprotective and restorative
role in brain damage.
On the other hand, astrocytes also contribute to the
inflammatory environment and facilitate the persistency of
the neurodegenerative process through the production and
release of proinflammatory cytokines [64]. Astrocytes are
able to produce and release a number of cytokines [65–67]
under the stimulation by different inflammatory-dependent
factors [65, 66, 68], having a clear impact in the neurode-
generative processes. This topic is extensively reviewed in
Section 4 of the present paper. However, astrocytic-derived
cytokines have other unsuspected implications such as the
control of neurotransmission at synaptic level, which goes
beyond the glial-mediated proinflammatory reaction [69,
70].
The particular anatomical location of astrocytes, near
endothelial cells, is also important for the maintenance of
the homeostasis and the regulation of the inflammatory
environment. Specifically, the secretion of specific cytokines
and chemokines at the verge of blood vessels is a crucial
phenomenon in regulating the extravasation of blood cells at
the areas of degeneration [51, 71, 72]. Astrocytes are responsi-
ble of the production and release of some chemokines, such
as CCL2, CCL3, and CCL5, which are fundamental for the
infiltration of macrophages and lymphocytes in the brain
parenchyma. This anatomical location is also important to
eliminate debris produced in the brain parenchyma through
the draining fluids. A recent report has shown that astrocyte
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(a) Normal SNpc tissue (b) Starting neuronal death (d) Recognition of target
Dopaminergic neurons
Surveilling microglia
Dopaminergic neuron dying T-cell infiltration
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Initiation of Parkinsonian
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Time
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Figure 2: Local inflammatory response to dopaminergic neuronal death. (a) In normal SNpc tissue, microglia screen the brain parenchyma
for changes. (b) In Parkinsonism, when dopaminergic neurons start dying, a number of signals, such as ATP or Ca2+, are released into the
parenchyma. (c) These signals induce the inflammation, characterized by the enrolment of neighbor microglial cells and the recruitment of
blood cells, such as T-cell lymphocytes or monocytes. (d) Microglial cells approach and contact damaged neurons. (d) Active microglial cells
establish engulfing gliapses with degenerating neurons. (e) Microglial cells engulf and phagocytose degenerating neurons to resolve the local
inflammation.The inflammatory response starts 24 h after the dopaminergic insult and is maintained during days until it is resolved. In mice,
it could be resolved within 72 h, while in primates it could continue for years.
participates actively in the clearance of interstitial solutes (as
amyloid-𝛽) through the aquaporin-4 channels, sinking the
content to the CSF [73]. This suggests that astrocytes may
also play important roles in other degenerative processes such
as PD. Unraveling the multifaceted functions of astrocytes in
neurodegenerative diseases, and specifically in dopaminergic
degeneration, will be a crucial aspect to be pursued in the
future research.
3.3. Role of Oligodendroglia in the Proinflammatory Response
in Parkinsonism. The role of oligodendroglia in the Parkin-
sonian pathology remains unclear and it has been mostly
ignored. Few studies have been published reporting oligo-
dendroglial alterations in Parkinsonism [74]. One of the
limitations to study this phenomenon lies in the fact that
nigrostriatal dopaminergic fibers are poorly myelinated.
Besides, oligodendrocytes are very shifting and complex cells;
thus, their alterations due to neurodegeneration are difficult
to address in the adult brain. Oligodendrocyte phenotype
and protein expression change during axon re-myelination
[75], and it is reasonable to think that similar changes may
occur in oligodendrocytes after neuronal degeneration. In
response to demyelinating injury, oligodendrocyte precursor
cells undergo changes in morphology and upregulate several
transcription factor genes, such as OLIG2, NKX2.2, or MYT1
[75], to initiate the process of remyelination. However, the
response of mature oligodendrocytes after axon loss remains
scarcely explored.
Very few studies have been published regarding oligoden-
drocyte reactions after dopaminergic axon loss in PD. The
presence of complement-activated oligodendrocytes in the
SN of PD patients has been described [76], but its biological
significance and the link with the inflammatory response
remain unclear. Other groups have described the presence
of inclusions of 𝛼-synuclein in oligodendrocytes of the
nigrostriatal pathway of patientswith PD [77], which suggests
a direct implication of this cell type in the neuropathological
disease.
Regarding experimental models of PD, myelinated fibers
appear disrupted in MPTP-induced Parkinsonism in mice
[78], but little information is given about the state of the
wrapping oligodendrocytes around dopaminergic fibers after
degeneration. A recent report has shown that mature oligo-
dendrocytes, expressing myelin basic protein (MBP), are
overreactive in MPTP models of PD [79]. In Parkinsonian
mice, MBP-oligodendrocytes appear increased in numbers
and with a reactive phenotype, characterized by a larger
cell body size and an increase of the number of ramifica-
tions, selectively in the areas of dopaminergic degeneration
[79]. In mice, this reaction disappears few days after the
neurotoxic insult, and oligodendrocytes go back to their
normal morphological state, similar to the microglial and
astroglial reactive phenotypical changes [79]. In primates,
however, MBP-oligodendrocytes still display reactive phe-
notype years after the MPTP insult and appear increased
in numbers, showing persistent MBP immune reactivity
with respect to controls. Importantly, these changes are
concomitant to microglial and astroglial reaction, suggest-
ing an inflammatory-related phenomenon [79]. Neverthe-
less, the mechanisms driving this changes in oligodendro-
cytes after MPTP insult and its link with the proinflam-
matory environment are scarcely explored. Due to their
fundamental role in restoration of axons, the analysis of
oligodendrocytes in PD should be emphasized and further
evaluated. Comprehensive disease-modifying therapies must
take into account all cell types, including oligodendrocytes,
and be considered as possible cellular targets to treat the
disease.
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Figure 3: Graphical diagram of the motility and polarization of microglial cells in dopaminergic degeneration. Dopaminergic neuronal
death generates the release of products, such as ATP or Ca2+, which activates the surrounding microglia. These gradients are able to attract
microglia toward neurons (find-me signal). Cdc42/ROCK-dependent signaling controls themotility and polarization ofmicroglia, which can
be blocked by specific ROCK inhibitors.Themotility of microglia starts with the polarization of microglial processes and then the apposition
of the microglial cell body toward the neuron, forming an engulfing gliapse. In the engulfing process, dopaminergic neuron nucleus starts to
show chromatin condensation and displays a pyknotic appearance. Cathepsin-D lysosomes digest the content of the phagosome (modified
from [42]).
4. Proinflammatory Cytokines as
Crucial Factors of Glial-Mediated
Inflammation in Parkinsonism
4.1. Increase of Proinflammatory Cytokines in the Glial-Medi-
ated Inflammation in Parkinsonism. Together with the histo-
logical findings obtained from postmortem studies, the evalu-
ation of peripheral inflammatorymarkers, such as proinflam-
matory cytokines in the blood or cerebrospinal fluid (CSF),
has been an important analysis in patients with PD. The
first proinflammatory cytokine detected in high levels in the
blood and the CSF of patients with PD was tumor necrosis
factor-𝛼 (TNF-𝛼) [80]. This finding was relevant because (1)
it confirmed that the inflammatory response, taking place
in PD patients, goes beyond the brain parenchyma, and (2)
because TNF-𝛼 is a cytokine able to induce cell death through
the activation of TNF-𝛼 receptors (TNF-𝛼R). The binding of
TNF-𝛼R by TNF-𝛼 stimulates a signaling cascade that acti-
vates proapoptotic domains inducing neuronal death [81, 82].
TNF-𝛼R are present on the membrane of human dopamin-
ergic neurons, indicating that a TNF-𝛼-dependent proin-
flammatory environment could directly affect the apoptotic
signal of vulnerable neurons within the SN of PD patients
[83].
In PD experimentalmodels,mice lacking TNF-𝛼 or TNF-
𝛼R are less susceptible toMPTP-induced neuro-degeneration
[84, 85]. Conversely, the long-term and artificially induced
expression of TNF-𝛼 exacerbates dopaminergic degenera-
tion, together with the stimulation of a sustained inflamma-
tory response in the brain [86]. In Parkinsonian primates,
unlike other cytokines, TNF-𝛼 plays a central role in the
long-term inflammatory potentiation of Parkinsonism [87,
88]. However, the question that remains unsolved is whether
endogenous circulating TNF-𝛼 may cause new neuronal
degeneration in a self-perpetuated inflammatory environ-
ment in primates.
In addition, the proinflammatory cytokine interferon
(IFN)-𝛾 has also been found increased in plasma of patients
with PD, and it has been shown to have an important impact
in the inflammatory response involved in dopaminergic
degeneration [89]. In experimentalmodels of PD, IFN-𝛾 defi-
cient mice are protected against MPTP-induced dopaminer-
gic degeneration and display attenuated local inflammatory
response [89]. Since IFN-𝛾R is not present on dopaminergic
neuron’s membrane, in contrast with TNF-𝛼, the role of IFN-
𝛾 in dopaminergic neuro-degeneration does not affect neu-
rons directly. IFN-𝛾 activates bystander glial cells and con-
tributes to the local inflammatory-mediated neuronal degen-
eration [88, 89]. Recent results obtained from chronic Parkin-
sonian macaque monkeys show that IFN-𝛾 appears elevated
in plasma and brain parenchyma, and similar to TNF-𝛼, it
seems to play a critical role in the long-term maintenance
of the inflammatory response in Parkinsonism [88]. Chronic
Parkinsonian monkeys maintain elevated amounts of both
cytokines, TNF-𝛼 and IFN-𝛾, during years, and the amounts
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correlate positively with the degree of Parkinsonism, as
well as the level of neuronal degeneration [88]. The impor-
tance of the latter results obtained in primates underlies in
the fact that they are comparable to the human scenario and
could be better extrapolated in terms of therapeutic strategies.
Thus, targeting TNF-𝛼 and IFN-𝛾might be the best approach
to diminish Parkinsonian inflammation in a chronic process.
Other proinflammatory cytokines, such as interleukin-
(IL-) 1𝛽, IL-2, IL-4, and IL-6, were also found elevated
in brain, blood, or CSF of PD patients [90–93]. However,
their specific function in PD is still poorly understood.
Experiments in vitro have shown that IL-1𝛽 and IL-6 are
relevant in promoting astroglial reactivation [94]. Some of
these cytokines are found elevated after dopaminergic insult
in mice and seem to play a critical role in promoting the
inflammatory response in acute models of PD in rodents
[95–97]. In contrast, in chronic Parkinsonian macaques, no
changes were seen in plasma levels of IL-1𝛽, IL-16, IL-6, IL-8,
and TNF-𝛽, which suggest that these cytokines may not play
a specific role in the long-term inflammation [88].
Rodents and primates seem to conduct differently regard-
ing the release of cytokines, similar to other proinflammatory
parameters such as microglial and astroglial activation. In
the case of MPTP-induced Parkinsonian mice, the high
levels of circulating cytokines are transient and parallel to
the glial inflammatory response observed in the local areas
of dopaminergic degeneration in the mouse brain [95–97].
Whereas in primates, circulating cytokines in serum and
brain can be detected even years after the initial MPTP insult
[88], which indicates that glial activation and the release of
cytokines are two phenomena that overlap (Figure 1).
4.2. Role of Proinflammatory Cytokines in Glial-Mediated
Inflammation and Neuronal Degeneration. The impact of
systemic and parenchymal circulation of proinflammatory
cytokines on the induction and maintenance of the glial-
mediated inflammation in vivo has been addressed with dif-
ferent approaches. Elegant experiments performed inmodels
of PD in rodents have shown that circulating cytokines,
such as TNF-𝛼 or IL-1, artificially induced by genetically
modified viral vectors, increase the inflammatory response
causing a deleterious effect on dopaminergic loss initiated
in the SN [98, 99]. The use of the bacteria membrane-
derived lipopolysaccharide (LPS) has also been an impor-
tant tool in order to understand how a non-PD-related-
induced inflammation could affect dopaminergic neurons.
The administration of LPS in midbrain cultures induces
dopaminergic degeneration together with the release of
cytokines such as TNF-𝛼 and IL-1𝛽 among others [100].
Similarly, the intraparenchymal injection of LPS in rodents
also induces a proinflammatory response that is toxic for
dopaminergic neurons, which are especially vulnerable to
the inflammatory insult [101, 102]. Furthermore, adding LPS
in combination with other neurotoxins, such as MPTP, is
synergistic and exacerbate both glial activation and neuro-
degeneration [103], suggesting that inflammation itself, inde-
pendent of the source, is deleterious for dopaminergic
neurons.
Cytokines function differently according to the specific
insults induced in the brain parenchyma [104]. Particularly
in PD, the initial cytokine-dependent inflammation may
represent an attempt to restore and repair the damage caused
in the neurodegenerative process. However, on the other
hand, the long-term exposure to increased levels of cytokines
could have deleterious consequences for the remnant neurons
[54, 105]. It is known that circulating cytokines induce
glial activation, which leads to new cytokine release by
bystander glial cells. This response creates a vicious cycle
where the proinflammatory environment itself may con-
tribute to induce new neuronal degeneration, establishing
a chronic process (Figure 4) [88, 106–108]. In summary,
the increased levels of certain cytokines, systemically or in
the brain parenchyma, could be a self-perpetuating factor
of the proinflammatory environment able to contribute and
accelerate the neurodegenerative process [109, 110].
From a therapeutic point of view, it is difficult to ascertain
which cytokines are the most deleterious for dopaminergic
neurons or which ones are able to promote a long-term
process. According to previous publications, and with the
data obtained so far, TNF-𝛼 seems to have a direct and promi-
nent role in the Parkinsonian dopaminergic degeneration.
However, proinflammatory environments are multifaceted,
and the increase of one particular cytokine is accompanied by
the stimulation, production, and release of others. Although
it is challenging to highlight a single cytokine to block in
order to avert inflammation in Parkinsonian degeneration, it
is necessary to determine optimal effective therapeutic targets
to diminish the proinflammatory environment to develop
disease-modifying therapies.
4.3. Proinflammatory Cytokines and Glial Cell Crosstalk in
Parkinsonism. There is an ongoing debate regarding the
cellular source of cytokines in the brain in vivo. The most
likely candidates for local production and release of proin-
flammatory cytokines in the brain are the glial cells, mainly
microglia and astrocytes [89, 111–113]. In addition, cells
coming from lymphoid tissues, the CSF, and the blood,
such as monocytes/macrophages or lymphocytes may also
participate in the local cytokine production and release in the
inflamed brain.
Studies in vitro show that glial cells produce and release
proinflammatory cytokines after different stimulus. However,
very few studies have been able to demonstrate this in vivo.
Technically, the detection of cytokines directly in fixed tissue
is challenging, and a few commercially available antibodies
give a convincing immunostaining in brain tissue. In a recent
article of our group, we show with immunofluorescence and
detailed confocal analyses the expression of cytokines in
glial cells in the SNpc of chronic Parkinsonian macaques
[88]. Histologically, we observed that TNF-𝛼 is expressed
fundamentally in reactive astrocytes in the areas of degen-
eration, while IFN-𝛾 appears to be detected only in reactive
microglia [88]. The expression of TNF-𝛼 by astrocytes is
well accepted; however, the IFN-𝛾 production and release
by cells of myeloid origin, such microglia/macrophages,
are still controversial [114]. Nevertheless, keeping in mind
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Figure 4: Diagram of the hypothetical vicious cycle of glial activation signaling triggered in Parkinsonism during dopaminergic neuronal
loss. (a) Dopaminergic neuronal death induces the release or leakage of ATP, which activates microglial cells through P2YR. (b) Activation
of microglia induces the release of IFN-𝛾, which binds IFN-𝛾R in neighbor microglial and astroglial cells initiating the phosphorylation
of STAT1. (c) Activation of astrocytes involves the release of TNF-𝛼, which may activate astrocytes through the activation of TNF-𝛼R by
phosphorylating SAPK. (d) Importantly, released TNF-𝛼 may also activate TNF-𝛼R present in dopaminergic neurons, which may induce
new neuronal death.
the controversy, it seems clear that there is a different cellular
localization of these two cytokines in chronic Parkinsonism
that reflects different contribution for both cell types in
the proinflammatory environment. We found that IFN-𝛾
receptor is expressed in astrocytes and microglia. Conse-
quently, the downstream cascade of activation of IFN-𝛾R,
characterized by the phosphorylation of STAT-1, appears
active in astrocytes and microglial cells, suggesting that IFN-
𝛾 signaling may play an important role in both astroglial and
microglial activation [88].
This data was obtained inMPTP-treated primates; thus, it
is difficult to ascertain the specific role of each proinflamma-
tory cytokine on the specific activation of glial cell activation
because it is a phenomenon that appears overlapped with
dopaminergic cell death in the long-term. However, in acute
MPTP-induced Parkinsonian models, glial activation can
be observed prior to dopaminergic degeneration, which
represents an important time window to evaluate the role
of cytokines using specific gene deletions with KO animals.
In fact, MPTP-treated mice lacking TNF-𝛼 or IFN-𝛾 show
important differences regarding glial cell activation before
dopaminergic degeneration can be achieved. After MPTP, in
the absence of IFN-𝛾, microglial cells get poorly activated,
whereas in the absence of TNF-𝛼, astroglial cells appear
inactive [88]. Thus, IFN-𝛾 seems to have a predominant
role on microglial activation, while TNF-𝛼 appears to have
a prominent effect on astroglial cell activation. According
to these results, cytokine signaling takes place differently
in astrocytes and microglia. In this context, the sequential
intervention of both cytokines may be very important for
the glial activation and its long-termmaintenance. As others,
we have suggested that astrocytes may work as amplifiers
of the inflammatory response initiated by microglial cells,
contributing to the dopaminergic cell death [111]. This syner-
gistic outcome may represent a crucial phenomenon for the
persistency of glial activation in Parkinsonism and could help
to find specific therapeutic anti-inflammatory drugs to target
cytokines to avert inflammation (Figure 4) [88]. Importantly,
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the role of TNF-𝛼 and IFN-𝛾 should be further evaluated,
especially in postmortem samples of Parkinsonian donors to
take additional steps toward therapeutic strategies for PD.
4.4. Contribution of T Cells in the Proinflammatory Envi-
ronment in Parkinsonism. The fact that cytokines and che-
mokines are able to recruit immune cells from the blood
stream into the brain parenchyma has led to investigate
the state of lymphocytes in Parkinsonian patients and in
experimental models of PD (Figure 1). Early studies in
Parkinsonian subjects have shown alterations of different T-
cell subpopulations. An increase of gamma delta T cells,
CD45RO+ memory T cells, and CD4+ T has been described
in peripheral blood [115] and CSF of PD patients [116].
However, the function of these T-cell subsets in dopaminergic
degeneration remains uncertain. Recent studies performed in
postmortem brains of PD patients have described that CD4+
T cells specifically infiltrate in the dopaminergic degenerating
areas [29]. Importantly, the putativemechanism of this subset
of infiltrated T cells has been investigated in experimental
models of PD. Parkinsonian rats and mice show an increase
of CD4+ and CD8+ T cells after the neurotoxic insult [30],
and similar to PD patients, active CD4 T cells are the subpop-
ulation of lymphocytes critically increased peripherally [117,
118] and in the brain [29, 119]. Importantly, the infiltration
of CD4 T cells seems to contribute to the dopaminergic
neuro-degeneration, as it has been demonstrated in KOmice
[29]. However, their particular involvement andmechanisms
are still not clarified. Theoretically, CD4 T cells search
for antigens displayed on MHC-II complexes (HLA-DR in
humans) in degenerating areas, which are probably displayed
bymacrophages ormicroglial cells, but the antigen thatmight
be presented by these MHC-II molecules is still conjectural.
Some reports have suggested that 𝛼-synuclein, or different
structural modifications of misfolded 𝛼-synuclein, may be a
plausible antigen to be presented, which would be consistent
with the hypothesis of an autoimmune disease, attacking
certain forms of the protein accumulated by dopaminergic
neurons [119]. This concept would involve the phagocytosis
of certain dopaminergic neurons by microglia/macrophages,
the digestion and processing of the protein, and the final
presentation of the antigen in the microglial membrane,
which remains to be elucidated. It is thought that Th17
response, a helper T-cell response involved in many autoim-
mune diseases, may be the adaptive immune response able
to guide this autoimmune-like reaction against dopaminergic
neurons. In fact, the immunization with nitrated 𝛼-synuclein
exacerbates the dopaminergic degeneration inMPTPmodels
in mice, which would support this hypothesis [120]. On
the other hand, not every immunization and infiltrated T-
cell population have the same effect on neurons. Studies
report that immunizations that stimulate the proliferation
and infiltration of certain T cells in the SNpc could be
protective for dopaminergic neurons inMPTP-inducedmice.
Copolymer 1-immunized mice show CD4 T-cell infiltration
in degenerating areas combined with IL-10 increase, which
indicates a regulatory compound of T cells in contrast with
the inflammatory Th17 autoimmune domain of T cells that
may contribute to degeneration in other scenarios [121, 122].
The balance in the amount of circulating cytokines, IL-
17 in Th17 response or IL-10 in regulatory responses, may
lead to the differentiation of specific lymphocyte populations
defining the degenerative outcome of the immune response.
Furthermore, changes in particular receptors on T-cell
surface may also contribute to the differentiation of lympho-
cyte response. It has been described that T lymphocytes in
PDpatients show changes in their cytokines receptor binding.
Particularly, IFN-𝛾 receptors are decreased in T cells of PD
patients, while TNF-𝛼 receptors are increased [123, 124]. This
suggests that the signaling of circulating cytokines such as
IFN-𝛾 and TNF-𝛼 may also alter the polarization towards
regulatory or inflammatory subsets modifying the outcome
of the immune response. The study of the function of T cells
in Parkinsonism represents a very promising field of research
for the upcoming years.
5. Putative Disease-Modifying
Anti-Inflammatory Drugs for PD
5.1. Nonsteroidal Anti-Inflammatory Drugs to Diminish Glial-
Mediated Inflammation in Parkinson’s Disease. Nonsteroidal
anti-inflammatory drugs (NSAIDs) are one of the most
reliable and promising therapies to avert the inflammatory
response in PD. NSAIDs have successfully been tested in
experimental models of Parkinsonism, reducing the brain
inflammation and protecting dopaminergic neurons [125,
126].This family of drugs includes compounds that inhibit the
enzyme cyclooxygenase- (COX-) 1 and/or 2 [127]. Aspirin, for
instance, inhibits both isoforms,while ibuprofen only inhibits
COX-2 [127]. In the light of the clinical and experimental
data, the use of COX-2 inhibitors seems to be the safest option
for long-term treatments since COX-1 inhibition may cause
damage of the gastric mucosa. Importantly, the epidemiolog-
ical studies also point out to COX-2 inhibitors, as Ibuprofen,
as the most effective anti-inflammatory drug reducing the
risk of PD [4, 128]. Importantly, three independent meta-
analyses have concluded that ibuprofenmay have a protective
effect in lowering the risk of PD [4, 128, 129].Themechanism
of action of COX-2 inhibitors in Parkinsonism seems to
directly reduce the glial-mediated local inflammation in
dopaminergic areas [130–133]. Particularly, the activation
of microglia in the dopaminergic pathway in experimental
Parkinsonism is mediated by COX-2 and contributes to
neuronal death [134]. In fact, COX-2-deficient mice are pro-
tected against MPTP-induced dopaminergic degeneration
and show reduced microglial inflammation, whereas mice
lacking COX-1 present similar neuronal loss than wild type
animals [130, 135]. Altogether, considering the safety and
effectiveness, these data suggest that COX-2 inhibitors may
be the drugs of choice for the treatment of PD [133, 136].
Regarding other anti-inflammatory drugs, new ap-
proaches have been tested that have successfully diminished
some aspects of microglial activation. ROCK pathway has
recently been described to play essential roles in microglial
activation and dopaminergic neuron survival [137, 138].
ROCK-mediated mechanisms are involved in important
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features of microglial activation such as the increase of
cell body size, increase of branches, and, importantly, the
motility of microglial cells towards damaged dopaminergic
neurons (Figure 3) [42]. Blocking ROCK reduces some
of the features of microglial activation and preserves neu-
rons from elimination [42]. Importantly, HA-1077, a potent
ROCK inhibitor, commercially available as Fasudil, preserves
neurons and fibers in MPTP models in mice and may
represent a promising drug to be used for PD patients.
In fact, Fasudil has the advantage that is currently used
for patients with vasospasm in Japan, which indicates that
Fasudil has already passed important steps regarding safety
and toxicity controls for human consumption. Another
approach that may be efficient in the near future involves
targeting cytokines. Despite the clear involvement of certain
cytokines in Parkinsonism, such as TNF-𝛼 and IFN-𝛾, the
possibility of treating patients with cytokine inhibitors is still
underdeveloped. There are a number of TNF-𝛼 and IFN-
𝛾 inhibitors designed with therapeutic purposes for other
immune-related diseases. Artificially generated antibodies
have been used successfully for autoimmune diseases such
as multiple sclerosis and Crohn disease [107]. However, to
predict the benefits for Parkinsonian patients may not be
clear enough, and the possible side effects may be still too
high to establish a solid therapeutic program. Furthermore,
inhibiting fundamental cytokines such as TNF-𝛼 and IFN-
𝛾 may also weaken unnecessarily the immune system of the
patients, which in elderly people may result in serious com-
plications. Thus, new therapies for PD have to demonstrate a
clear benefit/risk ratio to get into the market and the clinical
practice.
5.2. Glucocorticoids as a Potential Therapy to Diminish Glial-
Mediated Inflammation in Parkinson’s Disease. Glucocorti-
coids (GC) are potent anti-inflammatory drugs generally
used as effective treatment for many pathological conditions
and immune-related diseases. As inflammation has become
an important factor in PD pathogenesis, new studies have
recently been published regarding the implication of GC
in Parkinsonism [139, 140]. The inflammatory response,
involving the release of cytokines into the blood circulation,
has an effect on other anti-inflammatory systems such as the
hypothalamic adrenal axis.Thus, the input of cytokines in the
hypothalamus stimulates the release of ACTH that activates
the production of glucocorticoids and mineralocorticoids
from the adrenal gland, which may affect dopaminergic
degeneration [139]. In fact, Parkinsonian patients show alter-
ations in the adrenal axis, which in some cases are reflected in
the increase of cortisol levels [93, 140]. In acute experimental
models of PD, cortisol levels appear elevated weeks after the
neurotoxic dopaminergic insult [141]. In contrast, in chronic
Parkinsonian animals, no detectable modification of cortisol
release is seen years after the induction of the dopaminergic
degeneration [142]. These variations may reflect differences
in the level of affectation of the hypothalamic pituitary
axis between acute and chronic models of Parkinsonism.
However, the measurement of cortisol levels is somehow
controversial since the circulating amounts are susceptible
to change with many different variables, such as external
stressors, L-DOPA treatment, blood extraction schedule, and
circadian rhythms [142, 143]. Although the accuracy of sys-
temic measurements of circulating GC could be technically
questioned, it is reasonable to think that the increase of
GC may have physiological effects in the local inflammatory
environment in Parkinsonian subjects’ brains and conse-
quently on dopaminergic neurons. Since GC receptor (GR)
is ubiquitous, the presence of circulating GC may signal
specific responses at different levels in the brain, affect-
ing microglia, astroglia, and neurons. It has recently been
reported that the activation of the microglial GR has a crucial
effect in diminishing microglial cell activation and reduces
dopaminergic degeneration in experimental Parkinsonism
[140, 144].
Although GC may be effective in diminishing inflamma-
tion and could be considered as a promising option for PD
treatment, there are many variables that are still unmanage-
able, together with the putative side effects that long-termGC
treatments may provoke [145]. Key elements for the future
research in this field would be the determination of effective
doses with no deleterious effects and the development of
GC able to target cell-specific GR and particular anatomical
locations.
6. Concluding Remarks
Considering the latest experimental data, the epidemiological
studies, and genetic analysis, inflammation is yet considered
as an important contributor to dopaminergic degeneration
in Parkinsonism. The local activation of glial cells, together
with the chronic release of cytokines, and the putative role of
infiltrated players, such as T cells, indicate that inflammatory
response and immunity may be underling PD and may have
important consequences for dopaminergic neurons.
Among the common anti-inflammatory treatments com-
mercially available, NSAIDs and GC are the putative choices.
NSAIDshave been proven effective in preventing dopaminer-
gic degeneration and reducing the proinflammatory response
in experimental Parkinsonism. In the same way, GC such
as dexamethasone or corticosterone provides similar results.
Since the long-term treatment with GCmay cause unsuitable
side effects, COX-2 inhibitors, such as ibuprofen, seem to
be the most effective and safe anti-inflammatory treatment,
especially since it is supported by large-scale studies and
meta-analyses.
In conclusion, there are increasing lines of evidence
that anti-inflammatory drugs may be a beneficial treatment
for PD. Most importantly, these treatments may represent
a disease-modifying therapy in contrast with the current
therapies that only treat symptoms, as L-DOPA and other
dopaminergic agonists. However, it is still crucial to fully
evaluate the putative side effects and the safety of long-term
anti-inflammatory treatments, together with the study of the
evolution of the inflammatory response of the patients to
program new clinical trials with anti-inflammatory drugs for
PD in the near future.
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